Search

Displaying results 3971 - 3980 of 5898 in total
  1. Drug

    Zafiride

    go.drugbank.com/drugs/DB18371
    Investigational

    Zafiride is a human tumor necrosis factor coupled to the C terminus of CNGRCG peptide.

  2. Drug

    5-fluorotryptophan

    go.drugbank.com/drugs/DB03314
    Experimental

    5-fluorotryptophan can be used as substrate analogue to study enzyme mechanisms by NMR spectroscopy.

  3. Drug

    Uridine-5'-Diphosphate

    go.drugbank.com/drugs/DB03435
    Experimental

    A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety. [PubChem]

  4. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK. … GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline

  5. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions

  6. Drug

    Succinobucol

    go.drugbank.com/drugs/DB05399
    Investigational

    AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary

  7. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.

  8. Drug

    Phenoperidine

    go.drugbank.com/drugs/DB13605
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

  10. Drug

    Cathinone

    go.drugbank.com/drugs/DB01560
    ExperimentalIllicit

    Closely related to ephedrine, cathine and other amphetamines, it is probably the main contributor to the stimulant effect of Catha edulis. … Cathinone was added to the Controlled Substances Act's Schedule I in 1993 in compliance with international laws.